OTCMKTS:TKBIF Takara Bio (TKBIF) Stock Price, News & Analysis → Who are Nvidia’s New Silent Partners? (From Weiss Ratings) (Ad) Free TKBIF Stock Alerts $23.20 0.00 (0.00%) (As of 01/3/2023) Add Compare Share Share Today's Range$23.20▼$23.2050-Day Range$23.20▼$23.2052-Week Range$23.20▼$23.20VolumeN/AAverage Volume100 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Takara Bio alerts: Email Address Ad Crypto 101 MediaShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Takara Bio Stock (OTCMKTS:TKBIF)Takara Bio Inc., together with its subsidiaries, engages in bioindustry, contract development and manufacturing organization (CDMO), and gene therapy businesses in Japan, China, rest of Asia, the United States, Europe, and internationally. The company sells reagents and instruments, including genetic research reagents and testing kits; products related to coronavirus testing comprising in vitro diagnostics that detect viruses; analytical reagents; single-cell analysis systems; gene expression research reagents; fluorescent proteins series; genome-editing research reagents; iPS cell research reagents; and products for stem cell culturing and induction of differentiation under the TaKaRa, Clontech, and Cellartis brand names. It also provides contract services for regenerative medicine products, such as manufacturing of viral vectors and gene-transduced cells, quality and safety testing, and cell banking; and contract services for gene analysis and testing, including sequencing, intestinal flora analysis, comprehensive analysis of cancer-associated genes, and cell line creation through genome editing. In addition, the company is involved in developing platform technology for biologics development in areas, such as gene therapy. The company was incorporated in 2002 and is based in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.Read More TKBIF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TKBIF Stock News HeadlinesMay 9, 2024 | markets.businessinsider.comHere's what Wall Street expects from TAKARA BIO's earnings reportMay 6, 2024 | finance.yahoo.comTakara Bio Launches First Commercial Dissolvable Microfluidic Lentiviral Transduction EnhancerApril 2, 2024 | finance.yahoo.comTakara Bio transforms single-cell landscape with new large-scale NGS profiling system for oncology biomarker discoveryFebruary 8, 2024 | morningstar.comTakara Bio Inc TKBIFFebruary 5, 2024 | finance.yahoo.comTakara Bio’s First-to-Market Large-Scale Single-Cell NGS Profiling Technologies Poised to Revolutionize Biomarker DiscoveryDecember 11, 2023 | finance.yahoo.comTakara Bio USA Wins EU Opposition Hearing, Revoking Jumpcode Genomics’ NGS Library Enrichment PatentNovember 22, 2023 | wsj.comTakara Bio Inc.October 21, 2022 | investing.comTakara Bio Inc (4974)October 17, 2022 | finance.yahoo.comTakara Bio USA, Inc. and BioExcel Diagnostics Partner for Development of Wide-Coverage Infectious Disease Detection PanelsAugust 5, 2022 | markets.businessinsider.comTAKARA BIO earnings preview: what to expectNovember 9, 2021 | markets.businessinsider.comHere's what Wall Street expects from TAKARA BIO's earningsOctober 18, 2021 | finance.yahoo.comTakara Bio USA, Inc. Launches Automated, Full-Length Single-Cell RNA-seq Solution for Enhanced Biomarker DiscoveryJuly 25, 2021 | finance.yahoo.comTAKARA BIO INC (TKBIF) stock forecast and price targetSee More Headlines Receive TKBIF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Takara Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:TKBIF CUSIPN/A CIKN/A Webwww.takara-bio.com Phone81 77 565 6920FaxN/AEmployees1,539Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Koichi Nakao (Age 60)CEO, Pres & Representative Director Dr. Yoh Hamaoka Ph.D.Sr. Exec. Officer & DirectorMr. Tsuyoshi MiyamuraSr. Exec. Officer & DirectorMr. Junichi Mineno Ph.D.VP, Exec. Officer & DirectorMasanari Kitagawa Ph.D.Exec. OfficerMr. Masanobu Kimura M.S.MS, R.Ph., Exec. Officer & DirectorMutsumi Sano Ph.D.Sr. Exec. OfficerKatsuhiko KusakabeManaging Exec. OfficerMr. Andrew Farmer Ph.d.Head of R&DAkira KoderaExec. OfficerMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors TKBIF Stock Analysis - Frequently Asked Questions How have TKBIF shares performed in 2024? Takara Bio's stock was trading at $23.20 at the beginning of the year. Since then, TKBIF shares have increased by 0.0% and is now trading at $23.20. View the best growth stocks for 2024 here. Are investors shorting Takara Bio? Takara Bio saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 73,900 shares, an increase of 69.5% from the April 30th total of 43,600 shares. Based on an average daily volume of 0 shares, the short-interest ratio is currently ∞ days. View Takara Bio's Short Interest. How do I buy shares of Takara Bio? Shares of TKBIF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:TKBIF) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyOn June 10, Nvidia makes its next big moveWeiss RatingsMAJOR BUY SIGNAL: Move Fast, Washington/Pelosi/Mill…AltimetryUnlock Explosive Gains with This Defense StockBehind the MarketsElon’s Revenge on BidenTradeSmithClaim Your Complimentary Bitcoin RewardCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Takara Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.